Cytokinetics (CYTK) Tops Q1 EPS by 1c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.36), $0.01 better than the analyst estimate of ($1.37). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $3.6 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
- JPMorgan Upgrades Multi Commodity Exchange of India Ltd (MCX:IN) to Overweight
- Two Harbors rejects UWM Holdings lawsuit amid pending CrossCountry deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
